An open-label, multicenter extension study to evaluate the safety and
An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
The primary objective of the study is to determine the safety and immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg IV to subjects with multiple sclerosis who have completed natalizumab studies C-1801, C-1802, or C-1803.
Immune responseSafety
Loading reviews and guidelines…
Related trials
- Natalizumab and Chronic Inflammation
Phase 4 · Stopped early
Stopped
- Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Nata
Status unknown
No results found
- TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopa
Completed
No results found
- Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registrie
Completed
No results found
- Reduce the number of natalizumab infusions in patients with multiple s
Phase 4 · Ongoing
- Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
Completed
No results found
History
- In scope changed from true to false
Started
Jun 2004
Assembled by software from public sources.